Ferric Carboxymaltose Treatment to Improve Fatigue Symptoms in Iron-deficient Non-anaemic Women of Child Bearing Age

NCT ID: NCT01110356

Last Updated: 2012-11-15

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 294 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-06-30
• Study Completion Date: 2012-10-31

Brief Summary

research study of Ferric carboxymaltose to treat fatigue/exhaustion symptoms, believed to be due to iron deficiency.

Conditions

Iron Deficiency

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

Ferinject

Group Type: EXPERIMENTAL

Ferinject

Intervention Type: DRUG

Ferric carboxymaltose will be provided in 2 vials of 10 mL containing each 500 mg iron, which will be diluted in 250 mL normal saline for injection. Study drug will be administered by drip infusion immediately after preparation over a minimum of 15 minutes. Placebo patients will be administered 250 mL normal saline for injection over a minimum of 15 minutes.

Saline

Group Type: PLACEBO_COMPARATOR

Saline

Intervention Type: OTHER

Placebo patients will be administered 250 mL normal saline for intravenous drip over a minimum of 15 minutes.

Interventions

Ferinject

Ferric carboxymaltose will be provided in 2 vials of 10 mL containing each 500 mg iron, which will be diluted in 250 mL normal saline for injection. Study drug will be administered by drip infusion immediately after preparation over a minimum of 15 minutes. Placebo patients will be administered 250 mL normal saline for injection over a minimum of 15 minutes.

Intervention Type: DRUG

Saline

Placebo patients will be administered 250 mL normal saline for intravenous drip over a minimum of 15 minutes.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Signed informed consent prior to study specific procedures.
• Premenopausal, regularly menstruating women.
• Age ≥18 years.
• Body weight between 50 and 90 kg.
• Haemoglobin ≥115 g/L.
• Iron deficiency at screening defined as follows:
• S-ferritin level <50 ng/mL, AND, TfS <20%, OR,
• S-ferritin level <15 ng/mL.
• Serum C-reactive protein:
• <5 mg/L if not on oral contraception, OR,
• <20 mg/L if use of oral contraception.
• Minimum total score of 5 on the Piper Fatigue Scale (PFS) (mean of items 2 to 23).
• Negative pregnancy test (serum human chorionic gonadotropin (hCG) at screening.
• Normal levels of vitamin B12 and folic acid at screening.
• Adequate contraception during the study period and for 1 month following study completion.
• Availability and willingness to complete all study visits and procedures per protocol.

Exclusion Criteria

• Haemoglobin level <115 g/L.
• Haemoglobinopathy.
• Haemochromatose.
• Major depressive disorder based on Patient Health Questionnaire (PHQ-9) (5 items with scores ≥2; one of which corresponds to question number 1 or 2).
• Any active or unstable concurrent medical condition (e.g., cancer, renal dysfunction, liver dysfunction (aspartate aminotransferase (AST); alanine aminotransferase (ALT) >3-fold upper limit), angina (Class IV).
• Known human immunodeficiency virus/acquired immunodeficiency syndrome, hepatitis B virus or hepatitis C virus infection.
• Chronic inflammatory disease (e.g., rheumatoid arthritis; inflammatory bowel disease).
• Documented history of clinically significant level of sleep apnoea defined as 5 or more episodes per hour of any type of apnoea.
• Intake of concurrent medications that could interfere with physical or mental performance (e.g., antidepressive, antihistamines, narcotic or any chemotherapeutic agents known to cause drowsiness).
• Important recent weight loss (>10% within the past month).
• Body weight <50 kg or >90 kg.
• Thyroid dysfunction, thyroid stimulating hormone >4 μU/mL.
• Intake of iron preparations 4 weeks prior to screening.
• Use of gestagens e.g., Implanon, Mirena, Depo-Provera for menstruation repression (see Section 7.7, Prohibited Therapy or Concomitant Treatment, page 35).
• Known hypersensitivity to FCM or to any other iron preparation.
• Pregnancy (positive hCG test at screening) or breast feeding.
• Participation in any other interventional trial within 4 weeks prior to screening.
• Inability to fully comprehend and/or perform study procedures or provide written consent in the Investigator's opinion.
• Subject is not using adequate contraceptive precautions during the study and for up to 1 month after the last dose of the study medication. A highly effective method of birth control is defined as those which result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, some intra-uterine devices, sexual abstinence or vasectomised partner.
• Subject previously has entered this study.
• Subject will not be available for follow-up assessments.

• Minimum Eligible Age: 18 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

SGS S.A.

INDUSTRY

Sponsor Role: collaborator

Vifor Pharma

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Bernard Favrat

Role: PRINCIPAL_INVESTIGATOR

Quartier UNIL-CHUV

Locations

Universitätsklinik für Frauenheilkunde

Vienna, , Austria

Countries

Austria

References

Favrat B, Balck K, Breymann C, Hedenus M, Keller T, Mezzacasa A, Gasche C. Evaluation of a single dose of ferric carboxymaltose in fatigued, iron-deficient women--PREFER a randomized, placebo-controlled study. PLoS One. 2014 Apr 21;9(4):e94217. doi: 10.1371/journal.pone.0094217. eCollection 2014.

Reference Type: DERIVED

PMID: 24751822 (View on PubMed)

Other Identifiers

IDNA 2009-01

Identifier Type: -

Identifier Source: org_study_id